Group 1 - Yinlun Co., Ltd. plans to establish a joint venture company, Suzhou Yizhi Lingqiao Drive Technology Co., Ltd., with an investment of 10 million yuan, holding a 20% stake, to enhance the development of embodied intelligent robot components [1] - Zhimin Da's controlling shareholder plans to transfer 5.03 million shares, representing 3.00% of the total share capital, through an inquiry transfer method [1][2] - ST Ningke's subsidiary plans to invest 100 million yuan in a technical transformation project for the production of bio-fermentation products, aiming to enhance market competitiveness [3][4] Group 2 - Fujian Jinsen's chairman resigned due to work reasons, and the resignation will take effect after the election of a new chairman [5][6] - Kanghong Pharmaceutical's subsidiary received approval for clinical trials of Songling Xue Mai Kang capsules, aimed at treating functional ventricular premature beats [7][8] - Ruizhi Pharmaceutical plans to sell a 32.59% stake in its associate company, Guangdong Shenghetang Health Food Co., Ltd., for 60 million yuan [9] Group 3 - Meili Cloud's shareholder, China Metallurgical Paper Group, is undergoing bankruptcy reorganization, with its shares frozen and partially pledged [10] - Mongolian Grass Ecological plans to raise up to 1.495 billion yuan through a private placement for various ecological projects and working capital [11] - Aikelan's major shareholder plans to reduce their stake by up to 3% due to personal funding needs [12] Group 4 - Chaojie Co., Ltd. has three shareholders planning to reduce their stakes by a total of up to 3.73% for personal funding needs [13] - Haitai Biological's director plans to reduce their stake by up to 0.14% for personal funding needs [14] - New Guodu's executives plan to reduce their stakes by a total of up to 50.19 million shares for personal funding needs [15] Group 5 - Zhiguang Electric's vice chairman plans to reduce their stake by up to 304.06 million shares for personal funding needs [16] - *ST Jinbi's controlling shareholder plans to transfer 47.0853 million shares, making Yuan Yi Cheng Wu the new controlling shareholder [17][18] - Kaizhong Precision received a project designation from a leading global new energy battery manufacturer, with expected sales of approximately 700 million yuan [19][20] Group 6 - Defang Nano's director plans to reduce their stake by up to 133,200 shares for personal funding needs [21] - ST Hongtai's stock will have its risk warning removed, changing its name and increasing the price fluctuation limit [22] - Guoanda's directors plan to reduce their stakes by a total of up to 101,700 shares for personal funding needs [23] Group 7 - Lanshi Heavy Industry plans to acquire 100% of Qingdao Equipment for 99.9821 million yuan to enhance its delivery capabilities [24] - Qingdao Bank's major shareholder plans to increase its stake to no more than 19.99%, pending regulatory approval [25]

A股创新药概念持续活跃，海思科尾盘涨停，奥赛康此前涨停，舒泰神、睿智医药涨超10%，千红制 药、百济神州、长春高新涨超5%。 ...

智通财经6月12日电，午后创新药概念再度拉升，百济神州涨超7%，再创历史新高，此前奥赛康涨停， 荣昌生物、睿智医药、博瑞医药涨超10%，海思科、舒泰神、万邦德等多股涨超5%。消息面上，今日 智通财经记者获悉，港股创新药企中国生物制药在第46届高盛全球医疗健康年会上透露，今年将至少有 1个重量级的out-license交易落地。该股受此消息刺激大涨超15%，总市值突破1000亿港元。 创新药概念再度拉升 百济神州涨超7%创历史新高 ...

A股创新药概念再度活跃，奥赛康封板涨停，博瑞医药、睿智医药涨超10%，海思科、长春高新、微芯 生物、舒泰神等跟涨。 ...

Core Viewpoint - The company, Ruizhi Pharmaceutical, plans to transfer its 32.59% stake in Guangdong Shenghetang Health Food Co., Ltd. for a total price of 60 million yuan, resulting in no remaining ownership in Shenghetang after the transaction [1] Summary by Relevant Sections - **Transaction Details** - The total transaction price is 60 million yuan, with shares being transferred to individuals: Lu Wei, Wang Zhipeng, Wang Minggang, and Deng Yongzhong [1] - After the transaction, the shareholding structure of Shenghetang will be: Lu Wei 41.19%, Wang Zhipeng 27.42%, Wang Minggang 15.07%, and Deng Yongzhong 8.00% [1] - **Nature of the Transaction** - The transaction does not constitute a related party transaction and does not qualify as a major asset restructuring [1]

Core Viewpoint - The company plans to invest a total of 15 million yuan using its own funds to establish two wholly-owned subsidiaries in Guangzhou, aiming to expand its business and enhance core competitiveness and profitability [1] Group 1: Investment Details - The company will set up Guangzhou Ruiying Equity Investment Co., Ltd. with a registered capital of 10 million yuan, focusing on equity investment [1] - The second subsidiary, Guangzhou Ruilian Anmei Health Technology Co., Ltd., will have a registered capital of 5 million yuan, engaging in food sales and medical services [1] - The investment has been approved by the company's sixth board of directors at its eighth meeting, and management has been authorized to handle related matters [1] Group 2: Financial Impact - The funding for this investment will come from the company's own resources, ensuring that it will not adversely affect the company's financial status or operational performance [1]

根据睿智医药科技股份有限公司（以下简称"公司"）业务发展规划及战略布 局，公司拟使用自有资金合计 1,500 万元在广州分别设立全资子公司广州睿盈股 权投资有限公司、广州睿莲安美健康科技有限公司（暂定名，具体以市场监督管 理部门最终核准登记名称为准）。 证券代码：300149 证券简称：睿智医药 公告编号：2025-50 睿智医药科技股份有限公司 关于投资设立全资子公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 本次投资事项已经公司第六届董事会第八次会议审议通过，并授权公司管理 层办理本次投资相关事宜。本次投资事项在公司董事会决策权限内，无需提交公 司股东会审议批准。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关法律、 法规的规定，本次投资事项不构成关联交易，也不构成《上市公司重大资产重组 管理办法》规定的重大资产重组。 二、投资标的的基本情况 （一）广州睿盈股权投资有限公司 6、股权结构：公司持有广州睿盈股权投资有限公司 100%股权。 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-49 睿智医药科技股份有限公司 关于出售参股公司股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1、睿智医药科技股份有限公司（以下简称"公司"）拟对外转让持有的参 股公司广东生和堂健康食品股份有限公司（以下简称"生和堂"或"标的公司"） 32.59%股权，转让后，公司不再持有生和堂股权。 2、本次交易事项不构成关联交易，也不构成《上市公司重大资产重组管理 办法》中规定的重大资产重组情形。按照《深圳证券交易所创业板股票上市规则》 《公司章程》等相关规定，本次交易事项在公司董事会审议权限范围内，无需提 交公司股东会审议。 一、交易概述 根据公司发展战略，为进一步优化资源配置，提高投资效率，公司经与自然 人陆伟、王志鹏、王明刚、邓永忠协商一致，公司拟将持有的生和堂 32.59%股 权以合计人民币 6,000 万元的价格分别转让给陆伟、王志鹏、王明刚、邓永忠， 其中陆伟拟受让生和堂 7.93%股权；王志鹏拟受让生和堂 8.33%股权；王明刚拟 受让生和堂 8.33%股权；邓永忠拟受 ...

1、审议通过了《关于出售参股公司股权的议案》 根据公司发展战略，为进一步优化资源配置，提高投资效率，同意公司对外 转让参股公司广东生和堂健康食品股份有限公司 32.59%股权。本次交易完成后， 公司将不再持有广东生和堂健康食品股份有限公司股权。 本议案已经公司董事会战略与可持续发展委员会和独立董事专门会议审议 通过。具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）上披露的相关 公告。 证券代码：300149 证券简称：睿智医药 公告编号：2025-48 睿智医药科技股份有限公司 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第六届董事会第八次会议于 2025 年 6 月 9 日以通讯方式召开。会议通知以书面、电话或电子邮件方式送达。 会议应到董事 6 人，实到 6 人。会议由公司董事长 WOO SWEE LIAN 先生主持， 公司高级管理人员列席了会议。本次会议召集与召开符合有关法律、行政法规、 部门规章和《公司章程》的有关规定。经与会董事认真审议，形成决议如下： 本 ...

汽车配件、智慧农业、服务器、AI医疗概念股走强，种业、稀土、可控核聚变、新消费题材走弱。 （持续更新中……） 09:28 创新药概念延续涨势 塞力医疗逼近涨停，新开源、昂利康、联化科技、众生药业、睿智医药等集体高开。 | 代码 | 名称 | 涨幅↓. | 现价 | | --- | --- | --- | --- | | 002940 | 昂利康 | 49.98% | 26.11 | | 600557 | 康缘药业 | +9.97% | 16.32 | | 002317 | 众生药业 | +9.32% | 18.40 | | 688163 | 赛伦生物 | +7.61% | 22.07 | | 300109 | 新开源 | +6.77% | 18.57 | | 300482 | 赛升药业 | 45.63% | 13.43 | | 000078 | 海王生物 | +5.41% | 2.71 | | 301015 | 百洋医药 | +5.31% | 22.24 | | 603716 | 塞力医疗 | +5.13% | 14.13 | | 600513 | 联环药业 | +4.59% | 10.32 | 09:26 ...